Atossa Therapeutics Inc.
| NASDAQ: ATOS | Healthcare / Biotechnology / USA |
| 0.7350 | -0.0212 | -2.80% | Vol 186.34K | 1Y Perf 5.91% |
| Dec 6th, 2023 16:00 DELAYED |
| BID | 0.7250 | ASK | 0.7700 | ||
| Open | 0.7686 | Previous Close | 0.7562 | ||
| Pre-Market | - | After-Market | 0.77 | ||
| - - | 0.04 4.76% |
| Target Price | 4.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 444.22 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 26.40 | Earnings Rating | Buy | |
| Market Cap | 92.10M | Earnings Date | 6th Nov 2023 | |
| Alpha | 0.03 | Standard Deviation | 0.37 | |
| Beta | 1.21 |
Today's Price Range 0.72700.7700 | 52W Range 0.50001.39 | 5 Year PE Ratio Range -0.4000-0.5000 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | 3.57% | ||
| 1 Month | 11.21% | ||
| 3 Months | -2.17% | ||
| 6 Months | -20.40% | ||
| 1 Year | 5.91% | ||
| 3 Years | -48.91% | ||
| 5 Years | -41.83% | ||
| 10 Years | -99.84% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -47.50 | |||
ROE last 12 Months | -19.95 | |||
ROA (5Y Avg) | -8.64 | |||
ROA last 12 Months | -19.61 | |||
ROC (5Y Avg) | -154.06 | |||
ROC last 12 Months | -18.33 | |||
Return on invested Capital Q | -6.31 | |||
Return on invested Capital Y | -3.46 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -3.80 | ||||
| 0.74 | ||||
| - | ||||
| - | ||||
| -5.60 | ||||
| -0.16 | ||||
| 0.74 | ||||
| 0.98 | ||||
| -48 984 300.00 | ||||
| Forward PE | -2.92 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 41.10 | ||||
| 43.00 | ||||
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| Leverage Ratio | 1.00 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -0.06 | - |
| Q03 2023 | - | -0.05 | - |
| Q01 2023 | - | -0.05 | - |
| Q03 2022 | - | -0.06 | - |
| Q02 2022 | - | -0.05 | - |
| Q01 2022 | - | -0.04 | - |
| Q03 2021 | - | -0.04 | - |
| Q02 2021 | - | -0.06 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2018 QR | -0.65 | -16.07 | Negative |
| 12/2018 QR | -0.56 | 36.36 | Positive |
| 12/2023 FY | -0.24 | - | - |
| 12/2024 FY | -0.26 | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 186.34K |
| Shares Outstanding | 125.30K |
| Shares Float | 115.53M |
| Trades Count | 653 |
| Dollar Volume | 138.44K |
| Avg. Volume | 313.66K |
| Avg. Weekly Volume | 277.12K |
| Avg. Monthly Volume | 313.09K |
| Avg. Quarterly Volume | 350.79K |
Atossa Therapeutics Inc. (NASDAQ: ATOS) stock closed at 0.7562 per share at the end of the most recent trading day (a 2.88% change compared to the prior day closing price) with a volume of 247.73K shares and market capitalization of 92.10M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 6 people. Atossa Therapeutics Inc. CEO is Steven C. Quay.
The one-year performance of Atossa Therapeutics Inc. stock is 5.91%, while year-to-date (YTD) performance is 43.08%. ATOS stock has a five-year performance of -41.83%. Its 52-week range is between 0.5 and 1.39, which gives ATOS stock a 52-week price range ratio of 26.40%
Atossa Therapeutics Inc. currently has a PE ratio of -3.80, a price-to-book (PB) ratio of 0.74, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -19.61%, a ROC of -18.33% and a ROE of -19.95%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Atossa Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Atossa Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Atossa Therapeutics Inc. is Strong Buy (1), with a target price of $4, which is +444.22% compared to the current price. The earnings rating for Atossa Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Atossa Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Atossa Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.80, ATR14 : 0.05, CCI20 : 32.95, Chaikin Money Flow : 0.04, MACD : 0.02, Money Flow Index : 67.01, ROC : 11.22, RSI : 54.97, STOCH (14,3) : 62.17, STOCH RSI : 0.21, UO : 52.64, Williams %R : -37.83), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Atossa Therapeutics Inc. in the last 12-months were: Gregory L. Weaver (Sold 50 000 shares of value $32 500 )
Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage pharmaceutical company operating in the US. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The clinical-Stage Programs of the company includes delivery of therapeutics through microcatheters which delivers a number of therapeutics to the ducts in the breast, the site of the majority of early breast cancers and fulvestrant Delivered through microcatheters which delivers fulvestrant as a potential treatment of ductal carcinoma in-situ (DCIS) and breast cancer. In addition, the company involves in the process of evaluating additional potential indications of endoxifen and other therapeutic candidates to treat breast conditions, including breast cancer.
CEO: Steven C. Quay
Telephone: +1 206 325-6068
Address: 107 Spring Street, Seattle 98104, WA, US
Number of employees: 6
